Aligos Therapeutics, Inc.ALGSNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
71.27%
↑ 1038% above average
Average (28q)
6.27%
Historical baseline
Range
High:71.27%
Low:-47.88%
Volatility
1901.7%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 71.27% |
| Q2 2025 | -3.63% |
| Q1 2025 | -9.54% |
| Q4 2024 | -4.43% |
| Q3 2024 | -20.50% |
| Q2 2024 | 28.92% |
| Q1 2024 | -26.47% |
| Q4 2023 | 40.27% |
| Q3 2023 | -5.45% |
| Q2 2023 | -7.47% |
| Q1 2023 | -5.05% |
| Q4 2022 | 7.36% |
| Q3 2022 | 7.76% |
| Q2 2022 | -47.88% |
| Q1 2022 | 10.76% |
| Q4 2021 | 1.66% |
| Q3 2021 | 14.57% |
| Q2 2021 | 7.37% |
| Q1 2021 | -18.56% |
| Q4 2020 | 62.02% |
| Q3 2020 | 0.91% |
| Q2 2020 | -0.73% |
| Q1 2020 | 15.55% |
| Q4 2019 | 27.66% |
| Q3 2019 | 35.31% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |